AUTL Autolus Therapeutics Ltd - ADR

$AUTL I’m bullish on AUTL’s November 10 lupus trial update, as the early clinical results look very promising. Of the 12 patients treated, 10 achieved remission without background immunosuppressants, while all 12 showed remission or low disease activity. Patients with lupus-related kidney complications also showed improvement, with no major CAR-T-related safety concerns reported. Based on these results, I believe a positive update is more likely than a major disappointment.

$AUTL Adding to Gandolf below: - longer term follow up Carlysle data at ACR 11/6-11/11 Orlando - initial data Alaric at ASH 12/12-12/15 New Orleans - initial data ph 1 Bobcat ACTRIMS 3/11-3/13 Phoenix Reiterate from the recent William Blair report: - mgmt estimates Aucatzyl will surpass Tecartus this year (15-20% share of US adult ALL) - ALL treatment decisions highly physician driven so awareness is key - cash into 2q 2028 - cash flow positive by 2028 Continue to believe AUTL will come in above upper end of revised guidance - we shall see soon 🤞

$AUTL New to this ticker. can ppl kindly do a summary of upcoming catalysts and outlook?

$AUTL Gilead earnings: Tecartus's U.S. revenue is now down 40% year over year, compared with 29% in Q2. In today's Q3 release, the company describes the overall cell-therapy decline as reflecting ongoing competitive headwinds.

$AUTL This is my checklist for Nov 10. Opinion, not investment advice. A solid step up in revenue from Q2, not a flat or down quarter. Plan for EU and/or outside US/UK Reaffirming cash into Q2 2028 or later, with no sign of new dilution. Operating costs holding near the recent ~$69M a quarter, and gross margin improving toward the 55–60% range. More treatment centers, a manageable wait to get treated, outpatient numbers The remissions in the 12 patients holding at longer follow-up, with patients staying off immunosuppressants, no IEC-HS issues/deaths. With BMS and Novartis paused, this is probably obe-cel's biggest edge More complete renal responses in the lupus nephritis patients LUMINA enrollment on track, and a confirmed timing for the MS (BOBCAT) data. The warning signs would be revenue flat or down, a shorter runway, a new financing, any serious neurotoxicity or relapses in lupus, or delays to LUMINA.

$AUTL Most of the big Pharma money is going to in vivo because it is the "shiny new thing", which if it succeeds would be a major breakthrough in cost and ease of use. That being said autologous is the only proven durable treatment and with AUTL's safety breakthrough can now be used for more fragile patients, increasing the CAR T market size. In vivo, if proven is still many years away, you would think big Pharma would want to acquire a company with an FDA approved drug, generating revenue, and with an FDA approved factory to be used in case in vivo doesn't pan out or as a revenue bridge. My opinion, not advice...

$AUTL one eighth of the day's trading was in the last thirty minutes. Sellers tried to keep the close below 1.60 but 100K worth of bids came in at the last minute and moved the price back up. A lot of noise before the earnings. Rebalancing should tail off, options are done for now, so maybe we can get back to normal trading sessions instead of these nightly tug of wars.. Q3 earnings will be out soon and we will see where we all stand with AUTL.

$AUTL Caribou halts its allogeneic CAR T programs. Not a direct competitor but they had a CD19-targeting program. One more allogeneic program to fold and demonstrate how difficult to make it in this field.

$AUTL I don't think the current stock price reflects Autolus's potential. The situation looks much more positive now than it did when Wellington exited its position last year. I've also been following an MS patient on Instagram who has been sharing updates on her condition after receiving Autolus's CAR-T therapy. In her latest Reel, she mentioned that Autolus's Phase 1 MS trial had been completed and that preparations were underway for a Phase 2 trial. This is based on her account, so I'd like to see official confirmation and BOBCAT data from the company. Of course, the long-term data from CARLYSLE and the upcoming earnings call will be the near-term catalysts for us.

$AUTL we will get another pump after earnings or late Dec and Jan 2027. If you wanna sell, sell then. Dont let these people shake you out !

$AUTL Small purchase made. In the grand scheme of things not much added to my portfolio (~1150 shares), but the price was too good to pass up. I may whine from frustration but we will recover! Knocked down avg. another penny! Now $2.71 average 🙌

$AUTL Really misjudged this one, and I worked there for over a year! Product works great and is loved by clinicians, company not so loved. 🤞That the November catalysts can get me close to my average🤞

$AUTL Nothing left to say. Need a very good ER (which I expect) and solid SLE update in November (which I also expect) and 🙏 that starts the recovery, which I hope starts before EOY 🤞!

$AUTL so what has changed with the company since the stock was at $2.50? NOTHING. But it still sucks to see this price.

$AUTL hedge fund games. Three weeks before earnings they’ll flip and the stock will fly. Never fails.

$AUTL Key End-of-Year Catalysts and Milestones (2026) • AUTO8 in Light-Chain Amyloidosis: Initial data readout from the Phase 1 ALARIC trial is expected by the end of 2026. • Initial Autoimmune / MS Data: Initial clinical data for multiple sclerosis (MS) and autoimmune pipeline programs are targeted for late 2026. • AUCATZYL Commercial Execution: Continued tracking of U.S. net product revenues toward the full-year 2026 guidance range of $140–$150 million, positive gross margin targets, and expansion past 80 U.S. treatment centers.

$AUTL Doesn’t matter what XBI does, we only go down. Very frustrating stock for sure, but I know the game and holding long term. There will come a time when this stock will be irrationally doing the exact opposite and shorts will come on here to list all the reasons the run-up isn’t justified. Not investment advice!

$AUTL Blackstone warrants: expire on November 6 at $7.35 per ADS. These cover up to 3,265,306 ADSs. (Info only)

$AUTL bought more. The market is wicked..before next ER on November 11th they will pump up to 2$ and above

$AUTL got some buy orders ready. Only worry about the things you can control and the market is not one of them.